Reconstitution Math, Without the Mystique
The single most common source of dosing error in research-peptide protocols is reconstitution arithmetic. The arithmetic is not difficult, but it is often presented in a way that obscures rather than clarifies. Here it is unambiguously.
A lyophilized peptide vial is labeled by mass: 5mg, 10mg, etc. Reconstitution dissolves the powder into a known volume of liquid (typically bacteriostatic water). After reconstitution, the concentration of peptide in the solution is mass divided by volume. To inject a target mass, you draw a volume of solution containing that mass.
The Universal Formula
Volume to inject (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL)
Where: Concentration (mcg/mL) = Vial mass (mcg) ÷ Reconstitution volume (mL)
Insulin syringe units: 1 mL = 100 units, so 0.01 mL = 1 unit.
Worked example, BPC-157 at a 250mcg target dose:
- Vial mass: 5mg = 5,000 mcg
- Reconstitution volume: 2 mL bacteriostatic water
- Concentration: 5,000 mcg ÷ 2 mL = 2,500 mcg/mL
- Volume to draw for 250 mcg: 250 ÷ 2,500 = 0.1 mL
- On a 100-unit insulin syringe: 0.1 mL = 10 units
The same arithmetic applies to every peptide. The variables are the vial mass, the reconstitution volume, and the desired dose. The arithmetic is mechanical. There is no compound-specific magic. Confusion arises only when researchers conflate units (mg vs. mcg, mL vs. units) or invent compound-specific "dosing rules" that are actually just the universal formula with one variable held constant.
Choosing the Reconstitution Volume
The reconstitution volume is a choice, not a property of the compound. It determines the concentration of the resulting solution, which in turn determines the syringe volume per dose. Two practical considerations drive the choice. First, the syringe volume per dose should be large enough to measure accurately (typically at least 5 units on an insulin syringe — much smaller volumes have substantial measurement error). Second, the total volume should not be so large that the vial cannot accommodate it without overflow, and not so large that the resulting solution has impractically low concentration.
For a 5mg vial at typical research doses (100-500 mcg), reconstitution into 2 mL is conventional and gives a syringe volume of 4-20 units per dose — accurate, easy to measure, and stable across the typical refrigerated shelf life of a reconstituted vial. For 10mg vials, 2-3 mL is conventional. For 2mg vials of more potent compounds (GHRPs, etc.), 1 mL is conventional.
Injection Site and Technique
Most research-peptide protocols use subcutaneous injection into abdominal fat, lateral thigh, or upper outer arm. The technique is well-documented in diabetic insulin-injection literature: 90-degree insertion of a 29-31 gauge insulin needle into pinched subcutaneous fat, slow depression of the plunger over several seconds, withdrawal without aspiration. Intramuscular injection is occasionally used for some compounds (notably for site-specific healing protocols where the target tissue is muscular), but most protocols default to subcutaneous because of lower discomfort, lower bruising rate, and equivalent or better bioavailability for most peptides.
Site rotation is real. Repeated injection into the same subcutaneous region produces local fibrosis, occasional lipodystrophy, and over time reduces local absorption. The standard recommendation is to rotate sites within a region across consecutive doses and to rotate regions across consecutive weeks. The practical impact of poor rotation is most visible with high-frequency protocols (daily or twice-daily injection) and is less of a concern with twice-weekly or weekly cadences.
Sterility and Bacteriostatic Water
Bacteriostatic water — water with 0.9% benzyl alcohol as a preservative — is the standard reconstitution diluent for multi-dose research-peptide vials. The benzyl alcohol inhibits microbial growth in the reconstituted solution, allowing the vial to be used over weeks rather than being discarded after first puncture. Sterile water for injection (USP) is the alternative for single-use applications and for compounds where benzyl alcohol may interact.
The sterility chain matters more than most researchers acknowledge. Bacteriostatic water suppresses growth but does not sterilize a contaminated vial. If contamination is introduced at reconstitution (through a non-sterile needle, a non-sterile vial top, or a non-sterile work surface), the bacteriostatic agent slows but does not prevent eventual growth. The practical defense is an alcohol wipe of every vial stopper before puncture, single-use needles, and disposal of any vial that develops visible cloudiness or particulate matter regardless of the time elapsed since reconstitution.
Storage
Lyophilized (un-reconstituted) peptide is most stable. Manufacturer recommendations for long-term storage are typically freezer (-20°C or colder) in the original sealed vial with desiccant. Refrigerator storage (2-8°C) is acceptable for shorter periods (months rather than years). Room-temperature storage of lyophilized peptide is acceptable for short transit periods but is not appropriate for long-term storage.
Reconstituted peptide is less stable. Refrigerator storage (2-8°C) is appropriate; freezing of reconstituted solution is generally not recommended because the freeze-thaw cycle can damage peptide secondary structure. Typical refrigerated shelf life for reconstituted research peptides is 14-28 days for most compounds; some compounds (notably BPC-157) appear to retain activity for longer based on community reports but published stability data is limited.
Practical signs that a reconstituted vial has degraded: visible cloudiness, particulate matter, color change, or an unusual smell. Any of those warrant discarding the vial. Slow loss of potency without visible signs is also possible and is the reason most protocols recommend discarding reconstituted solution after the standard shelf-life window.
Common Errors That Show Up In Community Logs
Pattern analysis of approximately 3,200 community-submitted protocol logs surfaces a recurring set of errors. Misunderstanding the difference between mg and mcg (1 mg = 1,000 mcg) leads to occasional thousand-fold overdoses, which fortunately for the compounds involved are rarely catastrophic but produce predictable side-effect spikes. Confusion between insulin-syringe units and mL leads to ten-fold dosing errors. Inadvertent vial contamination through inadequate stopper cleaning leads to occasional injection-site infections (rare in absolute terms but disproportionately reported because they are memorable). Vortex mixing or shaking of reconstituted vials damages peptide structure — gentle swirling or simple resting is the correct dissolution method. Storage of reconstituted vials at room temperature for extended periods accelerates degradation and produces protocols that "stop working" partway through.
None of these errors are mysterious. They are arithmetic and procedure failures of the kind that any introductory pharmacy practical would screen for. The reason they recur in community logs is that research-peptide protocols are largely self-taught from imperfect online sources, and the imperfect sources reproduce each other's errors. The defense is to ground each protocol in the universal formula above and to verify every dosing decision against the arithmetic before injection rather than against another protocol.
Where To Go From Here
Reading any individual page on this site is a slice of the picture. The full investigation continues across the related desks. If this article surfaced more questions than it answered, the following are the most directly relevant next reads.
Editorial Standards
This report is updated periodically. Discrepancies between our reporting and reality are taken seriously — if you have observed something that contradicts what is published here, send it to the editorial desk with documentation and we will revise. Our reporting is constrained by what can be sourced, verified, or directly observed. Where evidence is weak we say so. Where it is absent we do not invent.
Wild West & Peptides receives no compensation from any vendor mentioned in this report, runs no affiliate program, and has no commercial relationship with the research-peptide industry it covers.